Thomas E. Willnow
Corporate Officer/Principal at Humboldt-Universität zu Berlin
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David E. R. Dangoor | M | 75 |
Humboldt-Universität zu Berlin
| - |
| Hans-Dieter Volk | M | - |
Humboldt-Universität zu Berlin
| 30 years |
| Jürgen Mlynek | M | - |
Humboldt-Universität zu Berlin
| 24 years |
| Christine Hohmann-Dennhardt | M | 74 |
Humboldt-Universität zu Berlin
| - |
| Michael W. Linscheid | M | - |
Humboldt-Universität zu Berlin
| - |
| Bernd Wegener | M | - |
Humboldt-Universität zu Berlin
| - |
| Christian Franke | M | - |
Humboldt-Universität zu Berlin
| - |
| Wolfgang Meyer-Sabellek | M | - |
Humboldt-Universität zu Berlin
| - |
| Barbara Lenz | M | 69 |
Humboldt-Universität zu Berlin
| 21 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stefan Koehler | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
| Christian Schneider | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
| Klaus Patzak | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
| Christine Maria Bortenlänger | M | 57 |
Ludwig-Maximilians-Universität München
| 6 years |
| Anders Nykjaer | M | - |
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | 9 years |
| Ludwig Fuchs | M | 58 |
Ludwig-Maximilians-Universität München
| 5 years |
| Marcus Englert | M | 59 |
Ludwig-Maximilians-Universität München
| 3 years |
| Carsten Reinhardt | M | 57 |
Ludwig-Maximilians-Universität München
| 5 years |
| Sven Oleownik | M | 60 |
Ludwig-Maximilians-Universität München
| 6 years |
| Andreas Beyer | M | 56 |
Ludwig-Maximilians-Universität München
| 5 years |
| Richard Mayer | M | 62 |
Ludwig-Maximilians-Universität München
| 6 years |
| Oliver Y. Maier | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
| Cornelius Baur | M | 61 |
Ludwig-Maximilians-Universität München
| 7 years |
| Florian Schulte | M | 53 |
Ludwig-Maximilians-Universität München
| 4 years |
| Kourosh Atabaki | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
| Antonio Cangeri | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
| Christian P. Illek | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
| Petra Denk | M | 52 |
Ludwig-Maximilians-Universität München
| 5 years |
| Stephan Feldhaus | M | 62 |
Ludwig-Maximilians-Universität München
| - |
| Ulrich Hauck | M | 60 |
Ludwig-Maximilians-Universität München
| 5 years |
| Kaspar von Braun | M | 53 |
Ludwig-Maximilians-Universität München
| 4 years |
| Wolfgang Neumann | M | 61 |
Ludwig-Maximilians-Universität München
| 3 years |
| Andreas von Maltzan | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
| Hans Schambye | M | 59 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | 3 years |
| Jacopo Mingazzini | M | 58 |
Ludwig-Maximilians-Universität München
| 6 years |
| Michael Salomon | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Katrin Leadley | M | 61 |
Ludwig-Maximilians-Universität München
| 3 years |
| Helene von Roeder | F | 54 |
Ludwig-Maximilians-Universität München
| 4 years |
| Gregor-Alexander Gerlach | M | 55 |
Ludwig-Maximilians-Universität München
| 4 years |
| Markus Saller | M | 62 |
Ludwig-Maximilians-Universität München
| 4 years |
| Thomas Tochtermann | M | 64 |
Ludwig-Maximilians-Universität München
| 3 years |
| Nicolas Peter | M | 62 |
Ludwig-Maximilians-Universität München
| 3 years |
| Nicolas Schobinger | M | 59 |
Ludwig-Maximilians-Universität München
| 4 years |
| Hubert Hofer | M | 61 |
Ludwig-Maximilians-Universität München
| 5 years |
| Shi Bo Tang | M | 63 |
Ludwig-Maximilians-Universität München
| 3 years |
| Patrick Martin | M | - |
Ludwig-Maximilians-Universität München
| 2 years |
| Jasper zu Putlitz | M | 61 |
Ludwig-Maximilians-Universität München
| 5 years |
| Jürgen Schrollinger | M | 56 |
Ludwig-Maximilians-Universität München
| 4 years |
| Wolfgang Stangl | M | 63 |
Ludwig-Maximilians-Universität München
| 4 years |
| Marek Borzymowski | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Michael Beck | M | 60 |
Ludwig-Maximilians-Universität München
| 6 years |
| Jan Anders Vedin | M | 82 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Florian Kaestle | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Ian Plimer | M | 76 |
Ludwig-Maximilians-Universität München
| - |
| Peter Pack | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
| Rainer Hackl | M | - |
Ludwig-Maximilians-Universität München
| 2 years |
| Stefan Leberfinger | M | 63 |
Ludwig-Maximilians-Universität München
| 3 years |
| Robert Walter | M | 59 |
Ludwig-Maximilians-Universität München
| 5 years |
| Steen Helde Hemmingsen | M | 80 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Ulf Roger Tossman | M | 68 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Hans-Henrik Horsted Eriksen | M | 64 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Palle Schelde Jensen | M | - |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Jørn Enggaard | M | - |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Anders Pedersen | M | 64 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | 3 years |
| Frank Appel | M | 62 |
Ludwig-Maximilians-Universität München
| 4 years |
| Mischa Hofmann | M | 56 |
Ludwig-Maximilians-Universität München
| 3 years |
| Dmitry Goncharov | M | 54 |
Ludwig-Maximilians-Universität München
| 4 years |
| Harald Emil Wilhelm | M | 58 |
Ludwig-Maximilians-Universität München
| 2 years |
| Thomas Vallon | M | - |
Ludwig-Maximilians-Universität München
| - |
| Ernest Paul Boles | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Adolf Hoess | M | 62 |
Ludwig-Maximilians-Universität München
| 3 years |
| Hans-Friedrich Elmar Liebler | M | 55 |
Ludwig-Maximilians-Universität München
| 5 years |
| Titus Weinheimer | M | 58 |
Ludwig-Maximilians-Universität München
| 3 years |
| Gabriele Multhoff | M | 63 |
Ludwig-Maximilians-Universität München
| 3 years |
| Andreas E. Haas | M | - |
Ludwig-Maximilians-Universität München
| 4 years |
| Moritz Mittelbach | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Alexander Betz | M | 52 |
Ludwig-Maximilians-Universität München
| 4 years |
| Charlotte Lohmann | F | 54 |
Ludwig-Maximilians-Universität München
| 3 years |
| Christian Thimann | M | 57 |
Ludwig-Maximilians-Universität München
| 3 years |
| Norman G. Neville | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 70 | 88.61% |
| Denmark | 9 | 11.39% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas E. Willnow
- Personal Network
